- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03201731
Social Isolation and Loneliness in Older People
Social Isolation and Loneliness in Very Late-onset Schizophrenia-like Psychosis: A Case-control Study
Although psychotic disorders such as schizophrenia usually present in late adolescence or early adulthood, research suggests that a substantial subset of people are diagnosed for the first time after the age of 60. This condition is referred to as 'very late-onset schizophrenia-like psychosis' (VLOSLP). People with VLOSLP are thought to experience high levels of social isolation, yet there has been little research systematically examining this. Additionally, little is known about how lonely people with VLOSLP feel, or how this group relate to and perceive other people.
This study aims to examine levels of social isolation and loneliness in patients with VLOSLP. The investigators also aim to explore aspects of social cognition in relation to VLOSLP.
A case-control study design will be used to examine the relationship between VLOSLP, loneliness, social isolation and social cognition. The case group will be people diagnosed with a non-organic psychotic disorder after age 60. The comparison group will be those aged 60 and above in contact with mental health services for a mental health difficulty, except from a psychotic disorder or dementia.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Cases
Inclusion criteria:
- Aged 60 and above.
- Diagnosed with a psychotic disorder after age 60.
Exclusion criteria:
- Diagnosed with a psychotic disorder before age 60.
- Dementia diagnosis.
- Mild cognitive impairment diagnosis.
- Clear organic cause for psychosis.
- Does not speak English to the degree needed to engage with study materials.
- Mental health problems too severe to fully engage with the study.
- Other medical or psychosocial factor that could limit ability to fully engage with study materials, such as severe intellectual disability or imminently life-limiting illness.
Controls
Inclusion criteria:
- Aged 60 and above.
- Diagnosed with any mental health disorder except from a psychotic disorder, dementia, or severe depression.
Exclusion criteria:
- Diagnosed psychotic disorder, drug-induced psychosis or organic psychosis.
- Dementia diagnosis.
- Mental health problems too severe to fully engage with the study.
- Does not speak English to the degree needed to engage with study materials.
- Other medical or psychosocial factor that could limit ability to fully engage with study materials, such as severe intellectual disability or imminently life-limiting illness.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Cases
Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
|
Controls
Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
UCLA loneliness Scale (version 3) (Russel, 1996)
Time Frame: Total assessment time: two hours
|
The UCLA loneliness scale is a 20-item measure of subjective feelings of loneliness.
The scale has been validated for use in the elderly.
Each item is scored from 1 (never) to 4 (often).
Items include 'I lack companionship' and 'People are around me but not with me'.
The scale yields an overall loneliness score between 0-80.
|
Total assessment time: two hours
|
Lubben Social Network Scale - 6 (LSNS-6) (Lubben et al., 2006)
Time Frame: Total assessment time: two hours
|
The LSNS-6 is a six-item self-report scale to assess social isolation in older adults by measuring perceived social support received from family and friends.
The scale assesses the size, closeness and frequency of contacts within a respondent's social network, with a subscale for friends and another for family.
Higher scores indicate larger social networks and lower scores indicate higher levels of social isolation.
Questions include 'How many relatives do you see or hear from at least once a month?' and 'How many friends do you feel at ease with that you can talk about private matters?'.
|
Total assessment time: two hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ambiguous Intentions Attribution Questionnaire (Combs, Penn, Wicher & Waldheter, 2007)
Time Frame: Total assessment time: two hours
|
This questionnaire is designed to examine attribution bias with a particular focus on hostile social-cognitive bias.
The researcher will read participants each vignette and ask them to imagine that the scenario is happening to them.
Participants rate whether the action was performed on purpose, with ratings from 1 (definitely no) to 6 (definitely yes), how angry it would make them feel from 1 (not at all angry) to 5 (very angry) and how much they would blame the other person from 1 (not at all) to 5 (very much).
These are totaled to create an overall score.
Responses to each item are averaged across scenarios and summed, with higher scores indicating greater blame.
|
Total assessment time: two hours
|
The Faux Pas test (Stone, Baron-Cohen & Knight, 1998)
Time Frame: Total assessment time: two hours
|
The Faux Pas test is designed to measure theory of mind, or the ability to make inferences about the thoughts, beliefs and intentions of others and to understand the possible motivations underlying others' actions.
In this test, theory of mind is measured using short vignettes followed by a series of questions.
We shall use a short version of the test developed by Negrão et al., (2016).
This test uses 5/10 faux pas stories and 5/10 control stories from the original Faux Pas Test.
After each story is read, participants will be asked five questions for: detecting a faux pas, understanding the faux pas, understanding the mental state of the faux pas recipient, understanding the mental state of the person delivering the faux pas and understanding the details but without making inferences about the mental states of the characters in the story.
|
Total assessment time: two hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17/0347
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Very Late Onset Schizophrenia
-
Jeremy KoppelNational Institute of Mental Health (NIMH)RecruitingLate Onset Schizophrenia | Delusional Disorder (Late Onset)United States
-
Indiana UniversityNational Institute on Aging (NIA)RecruitingDementia | Alzheimer Disease, Late OnsetUnited States
-
University of MinnesotaMayo Clinic; National Institute on Aging (NIA); University of St ThomasCompletedAlzheimer's Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.Invicro, Boston; Byrd Alzheimer's Institute, University of South Florida; University... and other collaboratorsCompletedAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Federal University of Minas GeraisCompletedAlzheimer Disease, Late Onset
-
Ohio State UniversityCompletedAlzheimer Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.University of South Florida Health / Byrd Alzheimer's InstituteUnknownAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownAlzheimer Disease, Late OnsetBelgium
-
IRCCS Centro San Giovanni di Dio FatebenefratelliI.R.C.C.S. Fondazione Santa Lucia; Ministero della Salute, ItalyRecruitingAlzheimer Disease | Alzheimer Disease, Late Onset | Cognitive DeteriorationItaly
-
Tamir Ben-HurHebrew University of JerusalemEnrolling by invitationAlzheimer Disease, Late OnsetIsrael